SCHEMBL4132984

SCHEMBL4132984

CN1C2CCC1CC(NC=O)C2

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 4/20 0.48
ADH1A P07327 4/20 0.48
ADH1C P00326 3/20 0.44
ADH7 P40394 2/20 0.44
ADH4 P08319 1/20 0.43
LMNA P02545 1/20 0.43
CYP2C9 P11712 1/20 0.43
KAT2B Q92831 1/20 0.43
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CHRM1 P11229 4/20 0.39
SLC6A2 P23975 4/20 0.39
SLC6A4 P31645 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13189336 0.92 ADH1B (0.52) ADH1BADH1AADH1CADH7ADH4
SCHEMBL1781470 0.92 ADH1B (0.52) ADH1BADH1AADH1CADH7ADH4
SCHEMBL19710108 0.75 ADH1B (0.44) ADH1BADH1AADH1CADH7ADH4
SCHEMBL14994637 0.75 LMNA (0.48) LMNACYP2C9KAT2BMEN1KMT2A
SCHEMBL21319727 0.72 ADH1B (0.65) ADH1BADH1AADH1CADH7ADH4
SCHEMBL25474174 0.72 LMNA (0.50) LMNACYP2C9KAT2BMEN1KMT2A
SCHEMBL1573740 0.72 LMNA (0.50) LMNACYP2C9KAT2BMEN1KMT2A
SCHEMBL1573739 0.72 LMNA (0.50) LMNACYP2C9KAT2BMEN1KMT2A
SCHEMBL18502846 0.72 LMNA (0.50) LMNACYP2C9KAT2BMEN1KMT2A
SCHEMBL12471683 0.71 LMNA (0.44) LMNACYP2C9KAT2BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796294-B2 Inhibitors of the hedgehog pathway EXELIXIS PATENT COMPANY LLC (US) 2014-08-05 US disclosed
US-8754092-B2 Inhibitors of the hedgehog pathway EXELIXIS PATENT COMPANY LLC (US) 2014-06-17 US disclosed
EP-2527330-A1 Inhibitors of the hedgehog pathway Exelixis, Inc. (US) 2012-11-28 EP disclosed
US-20120245139-A1 INHIBITORS OF THE HEDGEHOG PATHWAY EXELIXIS PATENT COMPANY LLC (US) 2012-09-27 US disclosed
US-20120238570-A1 INHIBITORS OF THE HEDGEHOG PATHWAY EXELIXIS PATENT COMPANY LLC (US) 2012-09-20 US disclosed
US-8222263-B2 Inhibitors of hedgehog pathway EXELIXIS PATENT COMPANY LLC (US) 2012-07-17 US disclosed
EP-2134695-A1 INHIBITORS OF THE HEDGEHOG PATHWAY Exelixis, Inc. (US) 2009-12-23 EP disclosed
US-20090105211-A1 INHIBITORS OF HEDGEHOG PATHWAY EXELIXIS, INC. (US) 2009-04-23 US disclosed
WO-2008112913-A1 INHIBITORS OF THE HEDGEHOG PATHWAY EXELIXIS, INC. (US) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238570-A1 INHIBITORS OF THE HEDGEHOG PATHWAY SHH, GLI1, SMO ADH1B 2266/4885ADH1A 2383/4885ADH1C 1896/4885
US-20090105211-A1 INHIBITORS OF HEDGEHOG PATHWAY SHH, GLI1, SMO ADH1B 2527/4885ADH1A 2464/4885ADH1C 2118/4885
US-20120245139-A1 INHIBITORS OF THE HEDGEHOG PATHWAY SHH, GLI1, SMO ADH1B 2266/4885ADH1A 2383/4885ADH1C 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.